Acute toxicity of postoperative radiochemotherapy with amifostine vs radiochemotherapy alone in head and neck cancer patients. Preliminary results of a randomized trial;Nebenwirkungen einer postoperativen radiochemotherapie mit amifostin versus alleiniger radiochemotherapie bei kopf-hals-tumoren: Vorlaufige ergebnisse einer prospektiv randomisierten untersuchung

Strahlentherapie und Onkologie

Volumn 175, Issue SUPPL.4, 1999, Pages 18-22

  Vacha, Peter ^a   Marx, Meinolf ^b   Engel, Arne ^b   Richter, Eckart ^b   Feyerabend, Thomas ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b NONE

Author keywords

Amifostine; Head and neck cancer; Postoperative radiochemotherapy

Indexed keywords

AMIFOSTINE; CARBOPLATIN;

ACUTE TOXICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; HEAD CANCER; HUMAN; LARYNX CANCER; MUCOSA INFLAMMATION; NECK CANCER; PHARYNX CANCER; RADIATION PROTECTION; SALIVARY GLAND; XEROSTOMIA;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SALIVARY GLANDS; STOMATITIS; TIME FACTORS; XEROSTOMIA;

EID: 0032748263     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Büntzel J, Kuttner K, Russel L, et al. Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. ASCO, 33rd Annual Meeting, Denver, USA, May 1997. Proc Am Soc Clin Oncol 1997;16:393a.
2. McDonald S, Meyerowitz C, Smudzin T, et al. Preliminary results of a pilote study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 1994;29:747-54.
3. Strnad V, Brizel D, Wannenmacher M, et al. Phase-III-Studie: Strahlentherapie + WR-2721 bei Patienten mit HNO-Tumoren - vorläufige Ergebnisse. Strahlenther Onkol 1997;173:561.
4. 35S-labeled WR-2721 in normal and malignant tissues of the mouse. Radiat Res 1976;68:284-91.
5. Utley JF, Seaver NA, Newton GL. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int J Radiat Oncol Biol Phys 1984;10:1552-8.
6. Vacha P, Marx M, Hakelberg K, et al. Prospektiv-randomisierte Anwendungsbeobachtung bei postoperativer Radio-Chemotherapie (RCT) und Amifostin-Medikation versus alleiniger RCT bei Larynx-Epi-, Oro- und Hvpopharynxkarzinomen - Erste Ergebnisse. Strahlenther Onkol 1997; 173:562.
7. Vacha P, Marx M, Engel A, et al. Acute toxicity of postoperative radiochemotherapy + amifostine vs radiochemotherapy alone in head and neck cancer patients: Preliminary results of a randomized trial. Radiother Oncol 1998;48:Suppl 1:40.
8. Wasserman TH. Radiotherapeutic studies with amifostine (Ethyol). Semin Oncol 1994;21:Suppl 11:21-5.